
Lilly and NextCure pen immuno-oncology deal; Lilly terminates deal
Executive Summary
Eli Lilly & Co. and NextCure Inc. partnered to discover and develop new immuno-oncology therapies utilizing NextCure’s FIND-IO (Functional, Integrated, NextCure Discovery in Immuno Oncology) platform.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com